PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
3877043-3	1985	These isozymes actively demethylate and oxidize these macrolides into nitrosoalkanes which form stable, inactive complexes with the iron of cytochrome P-450.	Macrolides	54-64	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-156	
22009620-10	2011	The primary number of clinically relevant pharmacological interactions is correlated with modifications of biotransformation of drugs due to Cytochrome P450 (CYP) hepatic enzymes which are involved in oxidative drug processes, including lipophilic antimicrobial drugs such as the macrolides, the fluoroquinolones (to be considered amphoteric) and the antifungal azole derivatives.	Macrolides	280-290	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	141-156	
22009620-10	2011	The primary number of clinically relevant pharmacological interactions is correlated with modifications of biotransformation of drugs due to Cytochrome P450 (CYP) hepatic enzymes which are involved in oxidative drug processes, including lipophilic antimicrobial drugs such as the macrolides, the fluoroquinolones (to be considered amphoteric) and the antifungal azole derivatives.	Macrolides	280-290	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-161	
1385058-1	1992	The hepatic cytochrome P-450 responsible for metabolism of the structurally related macrolides FK506 and rapamycin in humans was identified using in vitro studies.	Macrolides	84-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28	
9935275-9	1999	Increased macrolide use in children in recent years has resulted in a growing potential for drug interactions between them and other pharmacologically active agents via the inhibition of cytochrome P450 (CYP) microsomal enzymes.	Macrolides	10-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	187-202	
9935275-9	1999	Increased macrolide use in children in recent years has resulted in a growing potential for drug interactions between them and other pharmacologically active agents via the inhibition of cytochrome P450 (CYP) microsomal enzymes.	Macrolides	10-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	204-207	
8607732-2	1996	This results from macrolide inhibition of cytochrome P-450 metabolism of numerous xenobiotics, resulting in elevated serum drug levels and clinical intoxication.	Macrolides	18-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	42-58